MNPR-202 / National University of Singapore, Monopar Therap - LARVOL DELTA

A NOVEL ANTHRACYCLINE MNPR-202 DISPLAYS A DISTINCT IMMUNOMODULATORY PROFILE TO DOXORUBICIN IN DIFFUSE LARGE B CELL LYMPHOMA (ICML 2023) - "Although the combination therapy of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is curative, around 40% of patients relapse after first line treatment...Camsirubicin (MNPR-201; GPX-150; 5-imino-13-deoxydoxorubicin), a novel analog of dox, has not shown any irreversible heart damage to date in two Phase 1 trials and a Phase 2 trial...Finally, the drug screen revealed distinct differences in the synergy profile between dox and MNPR-202, e.g., with respect to volasertib... To conclude, dox and MNPR-202 have similar cytotoxic potencies, but likely work through different cellular pathways and have distinct drug synergies. Overall MNPR-202 appears to have greater immunomodulatory potential. Indeed, MNPR-202 ostensibly improves the anti-tumor response by exerting a stronger suppressive effect on M2-macrophage polarization."

Immunomodulating • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • NF-κβ • TNFA

Pre-Clinical Evaluation of a Camsirubicin Analog Mnpr-202 in Diffuse Large B Cell Lymphoma (ASH 2022) - "Diffuse large B cell lymphoma (DLBCL) is the most common subtype of aggressive lymphoma, for which the standard-of-care treatment is rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)...For example, a clear antagonistic effect on cell killing was seen between PLK1 inhibitor, volasertib, and doxorubicin, but between volasertib and MNPR-202, this antagonism was seen to a significantly lesser extent...These intracellular differences also influence drug synergies observed with the two chemotherapeutics, implying that in the context of certain combinatorial regimens, MNPR-202 may be superior to doxorubicin. Overall these findings suggest promise for further in vivo and clinical evaluation of MNPR-202 as a potentially effective yet non-cardiotoxic anthracycline derivative in lymphoma."

Preclinical • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immune Modulation • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • STING

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration (GlobeNewswire) - "Monopar Therapeutics Inc...released promising data with MNPR-202 from its ongoing collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS)....Data from blood cancer preclinical studies to date show that MNPR-202: has a similar cytotoxic potency to doxorubicin; generates increased DNA damage compared to doxorubicin; has a unique immune activation profile versus doxorubicin; demonstrates increased apoptosis compared to doxorubicin; causes a distinct set of genes to be upregulated and downregulated versus doxorubicin; and may be superior to doxorubicin in certain combination treatment regimens."

Preclinical • Hematological Malignancies • Oncology

Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) - "Validive – International Phase 2b/3 Trial, Interim Go/No-go Analysis on Track for Q1 2023....MNPR-202: Preclinical Data to be Presented at ASH 2022 in December....Early results from the open-label camsirubicin Phase 1b clinical trial will be presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Conference being held on November 16-19, 2022 in Vancouver, BC."

P2/3 data • Preclinical • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 (GlobeNewswire) - "Monopar Therapeutics Inc...will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial in Q1 2023."

Clinical data • P2/3 data • Preclinical • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor

Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting (GlobeNewswire) - "Monopar Therapeutics...announced that the abstract on its drug candidate MNPR-202 has been selected for a poster presentation at the 64th ASH Annual Meeting & Exposition (ASH 2022). ASH 2022....This poster will be the first release of data from Monopar’s ongoing collaboration with Dr. Anand Jeyasekharan of the Cancer Science Institute of Singapore, National University of Singapore Hospital."

Preclinical • Oncology

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer (GlobeNewswire) - “Monopar Therapeutics Inc…announced it has entered into a collaboration agreement with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer…While we expect camsirubicin to enter a dose escalation run-in clinical trial in advanced soft tissue sarcoma in the second half of this year…”

Licensing / partnership • New trial • Oncology • Sarcoma